title: [Intravitreal ranibizumab for choroidal neovascularisation associated with adult-onset vitelliform dystrophy].
abstract: METHODS
  A 70-year-old male patient diagnosed with bilateral adult-onset vitelliform dystrophy presented with a sudden decrease of vision in his left eye associated with the appearance of an occult type of neovascular membrane. It was treated with intravitreal ranibizumab due to juxtafoveal location of the membrane. Two injections were needed to induce total regression of the lesion.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab may be effective to induce morphological and functional improvement in cases of choroidal neovascularization secondary to adult-onset vitelliform foveomacular dystrophy. Further case series are required to confirm this observation.
authors.affiliation: Servicio de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, España. eprietocal@gmail.com
authors.forename: E
authors.initials: E
authors.lastname: Prieto-Calvo
authors.forename: C
authors.initials: C
authors.lastname: Torrón-Fernández Blanco
authors.forename: C
authors.initials: C
authors.lastname: Egea-Estopiñán
authors.forename: N
authors.initials: N
authors.lastname: Güerri-Monclús
authors.forename: E
authors.initials: E
authors.lastname: Ferrer-Novella
authors.forename: O
authors.initials: O
authors.lastname: Ruiz-Moreno
authors.forename: L E
authors.initials: LE
authors.lastname: Pablo-Julvez
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D057826:Vitelliform Macular Dystrophy / Q000150:complications*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab